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MaOBJECTIVES The aim of this study was to evaluate the impact of intravascular ultrasound (IVUS) guidance on the ﬁnal
volume of contrast agent used in patients undergoing percutaneous coronary intervention (PCI).
BACKGROUND To date, few approaches have been described to reduce the ﬁnal dose of contrast agent in PCIs. We
hypothesized that IVUS might serve as an alternative imaging tool to angiography in many steps during PCI, thereby
reducing the use of iodine contrast.
METHODS A total of 83 patients were randomized to angiography-guided PCI or IVUS-guided PCI; both groups were
treated according to a pre-deﬁned meticulous procedural strategy. The primary endpoint was the total volume contrast
agent used during PCI. Patients were followed clinically for an average of 4 months.
RESULTS The median total volume of contrast was 64.5 ml (interquartile range [IQR]: 42.8 to 97.0 ml; minimum, 19 ml;
maximum, 170 ml) in the angiography-guided group versus 20.0 ml (IQR: 12.5 to 30.0 ml; minimum, 3 ml; maximum,
54 ml) in the IVUS-guided group (p < 0.001). Similarly, the median volume of contrast/creatinine clearance ratio was
signiﬁcantly lower among patients treated with IVUS-guided PCI (1.0 [IQR: 0.6 to 1.9] vs. 0.4 [IQR: 0.2 to 0.6,
respectively; p < 0.001). In-hospital and 4-month outcomes were not different between patients randomized to
angiography-guided and IVUS-guided PCI.
CONCLUSIONS Thoughtful and extensive use of IVUS as the primary imaging tool to guide PCI is safe and markedly
reduces the volume of iodine contrast compared with angiography-alone guidance. The use of IVUS should be considered
for patients at high risk of contrast-induced acute kidney injury or volume overload undergoing coronary angioplasty.
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1288C ontrast-induced acute kidney injury(CI-AKI) is a potential complicationof diagnostic and therapeutic angio-
graphic procedures. Almost unanimously,
previous studies have shown that CI-AKI is
associated with worse clinical outcomes (1).
It remains debatable, however, whether
CI-AKI is solely a marker for future morbi-
mortality or, conversely, it is also causally
implicated in the occurrence of adverseevents (1,2).
A number of strategies have been tested to reduce
the incidence of CI-AKI. Vigorous ﬂuid administration
before and after the procedure is considered the most
important prophylactic scheme for patients at risk of
CI-AKI (3,4). Multiple other preventive measures
have been evaluated in clinical studies, but none has
been widely adopted, and, in practice, CI-AKI persists
as a major clinical problem for patients undergoing
angiographic procedures (4–13).SEE PAGE 1294Although the incidence of CI-AKI is modulated by
several clinical characteristics, the volume of iodine
contrast seems to be a major factor leading to CI-AKI,
independently of the baseline risk proﬁle (14–18).
Curiously, thus far, few approaches have been
described to reduce the primary cause of CI-AKI after
PCI, namely, the contrast agent dose (19–22). It is of
note that, in addition to be of potential beneﬁt forthe Volume of Contrast During Percutaneous
plied in Both Study Arms)
e clearance to ensure that contrast use does not to exceed a
ratio of 2. All actions should be taken to never exceed a ratio
coronary angiography to plan the interventional procedure
s, selection of treatment strategies) and anticipate potential
aphy was performed recently and of good quality, consider
phy during percutaneous coronary intervention. In this case,
played on an auxiliary video monitor, should be used as a
onitors with reference images of the target vessel anatomy
contrast) stent enhancement post-processing techniques.
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f contrast.
. Increased acquisition rates (i.e., >15 frames per second) may
o improve angiographic image quality, particularly in patients
-moving target segments (e.g., midright coronary artery or
entional material into the guiding catheter (e.g., balloons,
o make sure that the lumen of the catheter is free of contrast.patients at risk of CI-AKI, strategies to decrease the
use of contrast may also be valuable for other sub-
groups of patients, such as those at risk of volume
overload.
Intravascular ultrasound (IVUS) is largely used to
guide percutaneous coronary interventions (PCIs)
(23). Because of its ability to accurately measure
lumen, plaque, and vessel dimensions, it is possible
that IVUS might serve as an alternative tool to angi-
ography in many steps during PCI. We therefore
hypothesized that IVUS imaging during coronary
angioplasty may lead to a reduced use of contrast
media. The present report describes the primary end-
point analysis of the MOZART (Minimizing cOntrast
utiliZation With IVUS Guidance in coRonary angio-
plasTy) randomized controlled trial study, which
evaluated the impact of thorough IVUS guidance on
the ﬁnal dose of contrast agent used in patients un-
dergoing PCI.METHODS
PATIENT POPULATION. Patients 18 years of age or
older scheduled for PCI were considered for enroll-
ment in the MOZART trial. Included patients were at
high risk of CI-AKI or volume overload, according to
the presence of $1 of the following criteria: 1) older
than >75 years of age; 2) diabetes; 3) acute ischemic
syndrome needing urgent or emergent PCI; 4) creat-
inine clearance <60 ml/min/1.73 m2 or a single
remaining kidney or previous renal transplantation;
5) congestive heart failure, pulmonary congestion,
severe left ventricular dysfunction (ejection fraction
<45%), cardiogenic shock, or intra-aortic balloon
pumping. Angiographic eligibility required that all
target vessels be amenable to IVUS imaging at baseline
(i.e., before any balloon dilation), as judged by
an experienced interventionalist. Exclusion criteria
included use of iodinated contrast agents <72 h or
other nephrotoxic agents <7 days before procedure,
known allergy to contrast agents, and unstable or un-
known renal function before PCI. The study was
approved by the institutional review board, and signed
written informed consent was obtained from every
patient.
STUDY DESIGN, TREATMENT PROTOCOL, AND
FOLLOW-UP. All patients at high risk of CI-AKI
received intravenous hydration for 12 h pre- and 12 h
post-PCI. The interventional plan was left to the
discretion of the operator, but regardless of the allo-
cated arm, operators were strongly recommended to
follow strict strategies to reduce the total volume of
contrast for all patients, as summarized in Table 1.
TABLE 2 Technical Description of IVUS Guidance to Minimize Contrast Use
General rule: IVUS guidance aims to minimize contrast use. However, noncontrast radiographic
imaging is not precluded. Fluoroscopy and cine runs without contrast might be used
(and are encouraged), for instance, to visualize the stent limits and borders, identify the
position of IVUS probe inside the vessel, and register balloon expansion.
Aim for a single angiographic acquisition at baseline.
Extra baseline views are almost always unnecessary when using IVUS.
Use IVUS, not angiography, as the main source of information to plan PCI strategy.
Baseline as well as interim IVUS imaging runs should be used liberally to evaluate intervening
results and help plan the next steps.
Use baseline IVUS imaging to decide whether to use direct stenting.
For short, noncalciﬁed, not severely obstructive lesions, consider direct stenting.
Conversely, long ﬁbrocalciﬁed, diffusely diseased segments should undergo lesion
preparation, with balloon dilation or rotablation.
Use IVUS, not angiography, to check the results of pre-dilation.
The need for additional dilation and the occurrence of dissections are readily assessable
by IVUS.
For stent sizing, aim to use IVUS imaging only, not angiography.
Identiﬁcation of the proximal and distal reference segments is central to IVUS selection
of stent diameter and length.
Liberal use of manual IVUS imaging to precisely identify the 2 proximal and distal
reference spots.
Selection of stent diameter:
Stent diameter is primarily based on the size of reference segments.
IVUS guidance to select stent diameter is particularly informative in lesions with a large
disproportion between the reference segment sizes, in diffusely diseased arteries, or
lesions with extreme remodeling patterns (either positive or negative).
Selection of stent length:
Stent length should aim to cover from normal to normal segments ideally.
Stent length should be selected based on the longitudinal measurements of an IVUS
imaging run acquired with automatic pullback at known speed (preferably 0.5 mm/s).
Also, manual IVUS imaging can be used as an auxiliary practical way of assessing/conﬁrming
stent length. With the IVUS probe turned on in continuous imaging, the proximal and
distal reference points are iteratively selected. The distance between the chosen landing
zones can be easily measured manually using the length measurement registered in the
electronic display of the pullback device.
Minimize contrast using IVUS for stent positioning.
Obtain an x-ray (without contrast) with the IVUS probe at the proximal and distal
references spots.
Store these images and display them in an auxiliary monitor during stent placement to guide
positioning, minimizing contrast “pufﬁng.”
Use IVUS, not angiography, to verify the results of stent implantation.
Most often, stent underexpansion is better managed with higher pressure post-dilation with
an appropriately sized noncompliant balloon.
Incomplete apposition should be treated with post-dilation using appropriately sized
semicompliant balloons.
Use IVUS to judge the need for additional stenting and to select the size of the extra stent to
treat residual plaque or edge dissection.
Final results should be primarily assessed by IVUS imaging, not angiography.
Restrict ﬁnal angiography to 1 projection. There is no need for repeat angiography if
good-quality IVUS imaging shows satisfactory results.
Consider not performing a ﬁnal angiography in cases with a high conﬁdence of optimal
ﬁnal results.
IVUS ¼ intravascular ultrasound; PCI ¼ percutaneous coronary ultrasound.
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1289Saline (NaCl 0.9%) infusion was recommended at a
dose of 1 ml/kg body weight per hour (24) and reduced
to 0.5 ml/kg/h for those at high risk of volume over-
load (e.g., reduced left ventricular function or overt
heart failure) (15). The use of N-acetylcysteine or so-
dium bicarbonate was left to the operator’s discretion.
All percutaneous procedures were performed using
nonionic, low-osmolar or iso-osmolar, iodine-based
contrast media (iopromide [Ultravist, Bayer Pharma
AG, Berlin, Germany] or iodixanol [Visipaque, GE
Healthcare Ireland, Cork, Ireland]).
Patients were randomized nonblindedly in blocks
via an electronic system in a 1:1 ratio to angiography-
guided PCI or IVUS-guided PCI.
For those allocated to the IVUS-guided group, IVUS
imaging was performed with the Atlantis SR Pro Im-
aging Catheter 40 MHz connected to an iLab Ultra-
sound Imaging System (both by Boston Scientiﬁc
Corporation, Natick, Massachusetts). Vessels were
imaged during automated pullback at 0.5 mm/s, but
additional manual runs were strongly stimulated to
allow for detailed analysis of speciﬁc issues. Operators
were encouraged to use IVUS to the limit of its
potential, aiming to ultimately replace angiographic
imaging. Table 2 provides a detailed description of the
contrast-avoiding IVUS strategy. A ﬁnal IVUS pullback
was required to document the results at the end of
the procedure, targeting achievement of complete
stent apposition, without residual plaque burden at
the stent edges (ideally <50% plaque burden) or major
edge dissections and maximization of stent expansion
(ideally the intrastent minimal luminal area should
be >90% of the smallest reference lumen area).
After the index procedure, patients were followed
for 30 days with the main objective of detecting
safety clinical events, namely, death, myocardial in-
farction, or unplanned reinterventions.
ENDPOINTDEFINITIONSANDSTATISTICALCONSIDERATIONS.
The primary endpoint of the MOZART trial was the
total volume of contrast agent used during PCI. The
present report also analyzes the in-hospital and post-
discharge incidence of adverse clinical events, a pre-
deﬁned safety endpoint. All deaths were considered
for analysis. Myocardial infarctions were classiﬁed as
1) spontaneous; 2) secondary to ischemic imbalance;
3) leading to death with biomarkers unavailable; 4)
post-PCI; 5) post-coronary bypass surgery; or 6)
related to stent thrombosis (25). Stent thrombosis was
further classiﬁed according to the degree of certainty
as deﬁnite, probable, or possible (26). Unplanned
coronary reinterventions were computed if required
by a stenosis located in any segment of the epicardial
vessel treated at the index procedure.Cumulative air kerma (measured in gray), cumu-
lative dose-area product (measured in gray square
centimeters), and the number of cine runs were pro-
spectively collected as metrics for radiation dose. The
duration of the intervention was estimated by the
cumulative ﬂuoroscopic time (in minutes) and by
the procedure time (in minutes), deﬁned as the time
TABLE 3 Baseline and Procedural Characteristics
Angiography Guided
(n ¼ 42 )
IVUS Guided
(n ¼ 41) p Value
Age, yrs 62.1 (57.3–76.5) 67.1 (58.3–76.1) 0.3
Male 57.1 61.0 0.8
Hypertension 100 97.6 0.5
Smoking status 0.9
Never 59.5 58.5
Past 33.3 36.6
Current 7.1 4.9
Diabetes mellitus 81.0 73.2 0.4
Peripheral artery disease 4.8 4.9 >0.9
Previous stroke 4.8 12.2 0.3
Previous CABG 16.7 14.6 >0.9
Previous PCI 11.9 26.8 0.1
Clinical presentation >0.9
Silent ischemia or stable angina 71.4 75.6
Acute coronary syndrome 16.7 14.6
Ischemic equivalent* 11.9 9.8
Serum creatinine, mg/dl 1.1 (0.9–1.3) 1.2 (0.9–1.5) 0.4
Creatinine clearance,
ml/min/1.73 m2
72.4 (47.2–89.9) 60.5 (43.9–73.1) 0.2
Creatinine clearance
<60 ml/min/1.73 m2
40.5 48.8 0.5
Treated vessel
LMC 7.1 4.9 >0.9
LAD 52.4 34.1 0.1
LCx 28.6 46.3 0.1
RCA 35.7 22.0 0.2
Graft 2.4 9.8 0.2
Lesion type
A 9.5 2.4 0.4
B1 16.7 22.0 0.6
B2 35.7 24.4 0.3
C 64.3 63.4 >0.9
Bifurcation lesion† 26.2 24.4 0.5
Moderate or severe calciﬁcation 33.3 51.2 0.1
Pre-dilation 57.1 68.3 0.4
No. of stents 2.0 (1.0–2.3) 2.0 (1.0–2.0) 0.8
Overlapping stents 38.1 43.9 0.7
Stent diameter, mm 3.0 (3.0–3.5) 3.0 (2.8–3.5) 0.7
Stent diameter #2.5 mm 40.5 29.3 0.4
Total sum of stent length, mm 33.0 (22.3–54.5) 32.0 (20.0–46.0) 0.5
Stent length $20 mm 66.7 73.2 0.6
Post-dilation 78.6 95.1 0.048
Values are % or median (interquartile range). *Heart failure or arrhythmias documented related to
myocardial ischemia. †Deﬁned as a bifurcated target segment involving a side branch >2.0 mm in
diameter.
CABG ¼ coronary artery bypass graft surgery; LAD ¼ left anterior descending artery; LCx ¼ left
circumﬂex artery; LMC ¼ left main coronary; RCA ¼ right coronary artery; other abbreviations as
in Table 2.
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1290from the ﬁrst injection to the time the guiding cath-
eter was removed.
The creatinine clearance was calculated based on
the serum creatinine, using the equation proposed by
Cockcroft and Gault (27). For all patients, sequential
serum creatinine measurements were obtained on a
daily basis during the index hospitalization. Post-PCICI-AKI was deﬁned as any increase in baseline serum
creatinine values >0.5 mg/dl (28). A series of 25
consecutive patients with low creatinine clearance
(<60 ml/min/1.73 m2) undergoing angiography-
guided PCI at our institution (unpublished data) was
used as a basis for the sample size calculation. In that
cohort, the average volume of contrast was 147.6 
66.8 ml. A sample size of 80 patients was found to be
sufﬁcient to show a signiﬁcant reduction in the vol-
ume of contrast by 33% in the IVUS-guided group,
assuming a similar SD for both study groups, with an
alpha value of 0.05 and a beta value of 0.1. All ana-
lyses were carried out according to the intention-to-
treat principle. Categorical variables and adverse
events were presented as percentages and compared
using the Fisher exact test or the chi-square test.
Continuous variables were presented as median and
interquartile range and compared using the Mann-
Whitney U test. The incidence of post-discharge
adverse events was estimated according to the
Kaplan-Meier method and was compared between the
groups using the log-rank test. All p values were
2-tailed and were considered signiﬁcant if p < 0.05.RESULTS
Between November 2012 and September 2013, a total
of 83 patients were randomly allocated to
angiography-guided PCI (n ¼ 42) or IVUS-guided PCI
(n = 41). Patients’ characteristics at baseline were
similar between the study groups (Table 3). Overall,
the vast majority of the patients had diabetes mellitus
(77.1%), and most had stable coronary disease
(73.5%). The median serum creatinine of the study
population was 1.13 mg/dl (interquartile range [IQR]:
0.9 to 1.4 mg/dl), and 44.6% had a calculated creati-
nine clearance <66.0 ml/min/1.73 m2. A median of 2.0
stents (IQR: 1.0 to 2.0 stents) were used, and most
patients had complex target lesions (at least 1 type C
lesion in 63.9% of patients).
IODINE CONTRAST USE AND PROCEDURAL
CHARACTERISTICS. The total volume of contrast
(study’s primary endpoint) was 64.5 ml (IQR: 42.8 to
97.0 ml) (range, 19 to 170 ml) in the angiography-
guided group versus 20.0 ml (IQR: 12.5 to 30.0 ml)
(range, 3 to 54 ml) in the IVUS-guided group
(p < 0.001) (Table 4). Similarly, the volume of
contrast/creatinine clearance ratio was signiﬁcantly
different between the study groups (1.0 [IQR: 0.6 to
1.9] vs. 0.4 [IQR: 0.2 to 0.6], respectively; p < 0.001).
Low-osmolar contrast media were used in all patients
except 1 patient in the angiography-guided group who
was treated with an iso-osmolar agent (p > 0.9). Slight
TABLE 4 Iodine Contrast Use and Procedural Characteristics
Angiography Guided
(n ¼ 42)
IVUS Guided
(n ¼ 41) p Value
Total contrast volume, ml* 64.5 (42.8–97.0) 20.0 (12.5–30.0) <0.001
Volume of contrast per stent
implanted, ml
40.5 (25.7–48.3) 13.0 (7.1–20.0) <0.001
Contrast volume/creatinine
clearance ratio
1.0 (0.6–1.9) 0.4 (0.2–0.6) <0.001
Contrast volume/creatinine
clearance ratio >2
19.0 4.9 0.09
Procedure time, min 34.0 (18.5–54.5) 48.0 (34.0–61.0) 0.006
Fluoroscopy time, min 12.2 (6.8–24.1) 12.2 (8.4–20.8) 0.5
No. of cine runs 22.5 (16.0–36.3) 25.0 (19.0–32.5) 0.5
Cumulative DAP, Gy  cm2 82.1 (54.5–132.0) 73.7 (44.8–118.3) 0.4
Cumulative air kerma, Gy 1.4 (1.0–2.7) 1.4 (1.0–2.0) 0.3
Values are % or median (interquartile range). *Primary endpoint.
DAP ¼ dose-area product; IVUS ¼ intravascular ultrasound.
TABLE 5 In-Hospital and 4-Month Outcomes*
Angiography Guided
(n ¼ 42)
IVUS Guided
(n ¼ 41) p Value
In-hospital
Death 0 0 —
Acute myocardial infarction† 4.8 4.9 >0.9
Unplanned revascularization 0 0 —
Stent thrombosis 0 0 —
CK-MB increase >5 ULN 11.9 14.6 0.8
CK-MB peak, ng/ml 2.4 (1.3–3.7) 2.5 (1.1–9.4) 0.5
Peak serum creatinine, mg/dl 1.2 (1.0–1.5) 1.3 (1.0–1.6) 0.4
Lowest creatinine clearance,
ml/min/1.73 m2
61.9 (43.8–79.1) 51.4 (40.5–72.9) 0.3
Peak increase in creatinine
>0.5 mg/dl
19.0 7.3 0.2
4-month post-discharge
Death 0 4.2 0.3
Acute myocardial infarction‡ 3.3 4.2 >0.9
Unplanned revascularization 11.7 4.2 0.3
Stent thrombosis 0 0 —
Any event 11.7 4.2 0.3
Values are % or median (interquartile range). *Kaplan-Meier estimates. †All post-percutaneous
coronary intervention. ‡All spontaneous.
CK-MB ¼ creatine kinase-myocardial band; IVUS ¼ intravascular ultrasound; ULN ¼ upper limit
of normal.
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1291differences in indexes of renal function favored
neither group and were statistically indistinguishable.
The procedure time of IVUS-guided PCI was sig-
niﬁcantly longer than angiography-guided inter-
ventions (median difference, 14.0 min; p ¼ 0.006)
(Table 4). However, the groups did not differ with
regard to ﬂuoroscopic time, number of cine runs,
cumulative dose-area product, or cumulative air
kerma (p $ 0.3 for all) (Table 4).
IN-HOSPITAL AND POST-DISCHARGE OUTCOMES.
In-hospital outcomes during the index hospitaliza-
tion were not different between patients randomized
to angiography-guided or IVUS-guided PCI (Table 5).
The peak serum creatinine in the angiography-guided
PCI was 1.2 mg/dl (IQR: 1.0 to 1.5 mg/dl) versus 1.3
mg/dl (IQR: 1.0 to 1.6 mg/dl) in the IVUS-guided group
(p ¼ 0.4) (Table 5). Contrast-induced acute kidney
injury (i.e., increase in serum creatinine >0.5 mg/dl)
was diagnosed in 19.0% of patients treated with
angiography-guided PCI and 7.3% of those random-
ized to IVUS-guided PCI (p ¼ 0.2) (Table 5).
The median follow-up was 117 days (IQR, 45 to 177
days), there were no patients lost to follow-up, and all
patients had at least 1 month of post-discharge
follow-up. The incidence of death, myocardial in-
farction, unplanned revascularization, or stent
thrombosis was not signiﬁcantly different between
the study groups (Table 5).
DISCUSSION
The main ﬁnding of the present study was that PCI
performed primarily through IVUS imaging is safe
and signiﬁcantly reduces the dose of iodine contrast
compared with an angiography-only approach. The
mean contrast volume was 3-fold lower in the IVUS
compared with the angiography arm. Both study
groups were mainly composed of diabetic patients,
frequently with long, calciﬁed, bifurcated, and
complex lesions, who often needed multiple stent
implantation. It is of note that patients randomized
to the angiography group also received a relatively
low dose of contrast, particularly when considering
such a high-risk population (24), given rigid
contrast-saving strategies universally applied for
the whole patient cohort, as suggested by Nayak
et al. (20) and expanded in the present study. It
must be highlighted, therefore, that the effects of
IVUS guidance appeared to be an added beneﬁt in
contrast avoidance, in addition to already reduced
contrast use.
IVUS was extensively used in the MOZART trial,
almost as a substitute for angiography during PCI.
Such an approach was proven safe, with no excessiveuse of additional stents or increase in the incidence of
clinical adverse events. The IVUS-guided group had
slightly but signiﬁcantly longer procedures and
greater use of stents post-dilation, even though no
differences were noted in the number, length, or
diameter of stents, as well as in ﬂuoroscopy time, the
number of cine runs, or radiation dose. Most probably
the longer duration of IVUS-guided procedures
resulted from IVUS acquisition and interpretation.
This ﬁnding reinforces that speciﬁc IVUS training is
needed to obtain the maximal results from the tech-
nology, as well as to imprint ﬂuency to the procedure.
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1292Over the past years, optical coherence tomography
has been increasingly reported as an imaging tool to
guide PCI. The relative advantages and disadvantages
of optical coherence tomography over IVUS are yet to
be established. The much higher spatial resolution of
optical coherence tomography progressively estab-
lished it as an important method for in vivo evalua-
tion of lumen and plaque, as well as stent expansion,
apposition, and tissue coverage. Current guidelines
for the use of frequency-domain optical coherence
tomography recommend intracoronary administra-
tion of contrast for blood cleaning during image
acquisition. It is therefore improbable that the strat-
egy and results reported in the present study could be
directly extrapolated to contrast-based optical
coherence tomography imaging. Intracoronary saline
infusion could be explored as an alternative to
contrast media, even though the safety and diag-
nostic accuracy of this approach have yet to be
validated.
A number of previous randomized and ob-
servational studies evaluated the impact of IVUS
guidance on the outcomes after coronary stent im-
plantation, with recent meta-analytic data showing a
signiﬁcant decrease in the risk of adverse events
(23). Our study was not designed or powered to
detect differences in post-PCI renal function or
clinical outcomes. Nevertheless, paralleling the
decrease in contrast volume, patients treated with
IVUS-guided PCI showed a numerically (nonsigniﬁ-
cant) lower rate of post-PCI CI-AKI and adverse
cardiac events after the index procedure. Trends in
indexes of renal function that favor extensive IVUS
use might likely emerge in larger and adequately
designed studies.STUDY LIMITATIONS. Patients were enrolled in the
MOZART trial according to somewhat restricted
criteria, which excluded patients with recent cathe-
terization, using nephrotoxic agents, or with unstable
or unknown renal function. Such a study population
was selected mainly to reduce confounding factors in
assessing the impact of contrast saving on post-
procedure renal function and clinical outcomes. In
fact, in real-world practice, those patients would also
potentially beneﬁt from IVUS guidance. It is possible
that the increased interventional time and the use of
IVUS catheters would increase the costs of IVUS-
guided PCI. On the other hand, the reduction in
contrast use and an eventual decrease in complica-
tions could potentially offset the increased costs.
Further analysis in larger populations would be
desirable to evaluate the cost-effectiveness proﬁle of
IVUS use in CI-AKI–prone patients undergoing PCI.
CONCLUSIONS
Thoughtful and extensive use of IVUS as the primary
imaging tool to guide PCI is safe and markedly re-
duces the volume of iodine contrast used compared
with guidance by angiography alone. IVUS imaging
should be considered for patients at high risk of
CI-AKI or volume overload undergoing coronary
angioplasty.
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